Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.2% - Here's What Happened
Beam Therapeutics (NASDAQ:BEAM) saw its stock price drop 6.2% to $27.26 following a significant earnings miss. The company reported an EPS loss of $1.18 against an expected $1.11 loss, and revenue of $0.49 million, far below estimates of $16.37 million, marking a 94.2% year-over-year decline. Despite the poor financial results, analyst sentiment remains a "Moderate Buy" with an average price target of $49.00.
Beam Therapeutics (NASDAQ:BEAM) Shares Gap Up - Should You Buy?
Beam Therapeutics (NASDAQ:BEAM) shares gapped up 4.6% to $28.41, opening higher than its previous close of $26.57, despite reporting weaker-than-expected quarterly results with a significant revenue drop and a larger-than-anticipated loss per share. Analysts hold a "Moderate Buy" rating with a $49 price target, although company insiders have sold a substantial amount of shares recently. Institutional investors, however, maintain a strong ownership of 99.68% in the company.
Alphabet Inc. Purchases New Shares in Beam Therapeutics Inc. $BEAM
Alphabet Inc. has acquired a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM) during the second quarter, purchasing 321,604 shares valued at approximately $11.0 million, representing 0.31% ownership. Despite this institutional investment, Beam Therapeutics reported a quarterly loss and significant revenue decline, missing analyst estimates. The stock currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $49.00, though recent insider selling has also been noted.
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Beam Therapeutics Inc. (NASDAQ:BEAM) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $49.00. Despite this positive outlook, the company recently reported a quarterly loss of $1.18 per share, missing estimates, and revenue of $0.49 million, significantly below expectations and down 94.2% year-over-year. Insiders sold $10.5 million worth of stock, while institutional investors hold 99.68% of shares.
Beam Therapeutics (BEAM): ARK Investment and Cathie Wood report 9.95% stake
ARK Investment Management LLC and Cathie Wood have reported a beneficial ownership of 9.95% in Beam Therapeutics Inc. (BEAM), totaling 10,234,862 shares. This disclosure, filed via a SCHEDULE 13G/A, indicates that ARK has significant voting and dispositive power over these shares. The filing also notes that the ARK Innovation ETF is the only client with more than a 5% interest in these securities.
Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position
Farallon Capital Management and its affiliated funds have disclosed a beneficial ownership of 10,282,210 shares of Beam Therapeutics (BEAM) common stock, representing 9.99% of the outstanding class. This position includes directly held shares and common stock purchase warrants, with exercisability capped at 9.99% due to a beneficial ownership limitation. The filing details the ownership structure and key figures of this significant investment.
Analyst Forecasts Just Became More Bearish On Beam Therapeutics Inc. (NASDAQ:BEAM)
Analysts have issued a major negative revision to Beam Therapeutics Inc.'s near-term revenue forecasts for 2026, anticipating a significant decline in sales while losses per share are expected to balloon. Despite the drastic revenue downgrade, the consensus price target remains unchanged, suggesting analysts do not foresee a long-term impact on the company's valuation. However, the company's projected revenue decline of 90% by 2026 indicates it will lag behind the broader industry's growth.
Weekly Recap: H1 2026 financials and BEAM-302 pivotal cohort dosing
Beam Therapeutics (NASDAQ:BEAM) reported its H1 2026 financials, including $32.2M in revenue and a $217M net loss, with a cash position of ~$1.15B, extending its runway into mid-2029. The company also announced it has dosed the first patient in the pivotal global cohort for BEAM-302, targeting alpha-1 antitrypsin deficiency, moving towards potential accelerated U.S. approval.
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy
H.C. Wainwright has reiterated its Buy rating and an $80.00 price target for Beam Therapeutics Inc. (NASDAQ:BEAM), indicating a 64% potential upside. This endorsement follows Beam's positive clinical developments, including dosing the first patient in a pivotal trial for BEAM-302 and progress on other gene-editing therapies, despite a recent arbitration ruling against them concerning development rights for PM647.
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com
H.C. Wainwright has reiterated a Buy rating for Beam Therapeutics Inc. (NASDAQ:BEAM) with an $80.00 price target, suggesting a 64% upside. The company recently reported progress on its clinical trials for BEAM-302, BEACON, and BEAM-304, and is expecting updated data and regulatory submissions by year-end 2026. Despite a collaboration dispute ruling with Prime Medicine, other analysts maintain positive ratings, noting the specific nature of the ruling.
Analyst Forecasts Just Became More Bearish On Beam Therapeutics Inc. (NASDAQ:BEAM)
Analysts have significantly downgraded their near-term revenue forecasts for Beam Therapeutics Inc. (NASDAQ:BEAM), now expecting a 69% decline in sales for 2026, though loss per share estimates remain steady. Despite the bearish revenue outlook, the consensus price target of US$52.15 remains unchanged, suggesting analysts do not anticipate a long-term impact on valuation. The company's projected revenue decline is also expected to significantly lag the broader biotech industry.
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy
H.C. Wainwright has reiterated a Buy rating and an $80.00 price target for Beam Therapeutics Inc. (NASDAQ:BEAM), representing a 64% potential upside. The company is advancing several clinical programs, including BEAM-302 for AATD-associated lung disease, ristoglogene autogetemcel (risto-cel) with a biologics license application expected by year-end 2026, and BEAM-304 for phenylketonuria. Despite a recent arbitration ruling in favor of Prime Medicine regarding development rights for PM647, analysts maintain a positive outlook on Beam Therapeutics' pipeline and manufacturing capabilities.
(BEAM) and the Role of Price-Sensitive Allocations
This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM), highlighting a mid-channel oscillation pattern and an exceptional 62.6:1 risk-reward setup. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and time horizons. The analysis suggests a near-term strong sentiment, mid-term neutrality, and long-term positive bias for the stock.
Analysts Have Lowered Expectations For Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results
Analysts have lowered their revenue expectations for Beam Therapeutics Inc. (NASDAQ:BEAM) after the company reported second-quarter results that fell significantly short of estimates, with revenues missing by 97% and losses being higher than modeled. Despite the substantial haircut to revenue forecasts for 2026, the average price target for BEAM has remained largely unchanged, indicating analysts believe the long-term intrinsic value is unaffected. The company's revenues are now projected to decline significantly by 2026, performing much worse than the broader industry.
Analysts Have Lowered Expectations For Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results
Analysts have lowered their revenue expectations for Beam Therapeutics (NASDAQ:BEAM) after the company reported second-quarter results that fell short of estimates. While revenue forecasts for 2026 were significantly cut, loss per share estimates remained steady, and the average price target did not change, suggesting analysts don't foresee a long-term impact on valuation despite the short-term disappointment. The company's revenue is now expected to decline significantly, underperforming the broader biotech industry.
Beam Therapeutics Number of Employees 2026 | Employee Count & Headcount Data
Beam Therapeutics, Inc. (NASDAQ: BEAM) had approximately 517 employees worldwide as of March 2026, marking a 2.3% decline from 530 employees in 2023. Despite this overall decline, the company is actively hiring, with 71 active job postings in 2026, a 42.7% increase from 2025. The workforce is primarily concentrated in North America, with an average salary of $184,848.
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
Beam Therapeutics (BEAM) reported a wider-than-expected loss of $1.18 per share in Q2 2026, missing the Zacks Consensus Estimate of a $1.00 loss, and revenues fell significantly year-over-year. Despite the financial performance, the company is advancing its pipeline, including candidates for sickle cell disease (risto-cel), glycogen storage disease type Ia (BEAM-301), alpha-1 antitrypsin deficiency (BEAM-302), and phenylketonuria (BEAM-304), with several clinical data readouts and regulatory filings anticipated. The company maintains a strong cash position, expected to fund operations into mid-2029.
How Beam’s Wider Q2 Loss and Trial Progress Will Impact Beam Therapeutics (BEAM) Investors
Beam Therapeutics reported a wider net loss of US$122.68 million and a revenue shortfall in Q2 2026, yet achieved key clinical milestones including completing dosing for its risto-cel sickle cell trial and dosing the first patient in the BEAM-302 study. The article discusses how these developments, particularly the progress toward a risto-cel BLA filing, shape the company's investment outlook despite ongoing financial losses and potential risks related to conditioning regimens. Beam's investment narrative projects significant revenue and earnings growth by 2029, suggesting a potential 89% upside to its current price according to Simply Wall St's fair value analysis.
Beam Therapeutics Inc. Stock 12‑Month Price Target Cut to $51.07, Implies 80% Upside
Analysts have cut the average 12-month price target for Beam Therapeutics Inc. (BEAM) stock from $51.36 to $51.07, with individual forecasts ranging from $26 to $80 per share. This updated target suggests an 80% potential upside based on the Aug. 4 closing price. The consensus rating from 16 analysts remains a "Buy," with 14 Buys, 2 Holds, and 0 Sells.
Beam Therapeutics (BEAM) On A Wider Q2 Loss And The Valuation Debate
Beam Therapeutics (BEAM) reported a wider net loss and higher loss per share for Q2 2026, yet saw a short-term share price bounce. Despite a challenging longer-term stock performance, a "Most Popular Narrative" suggests the company is 44.5% undervalued with a fair value of $51.07, driven by expectations for its ESCAPE technology. However, this bullish outlook depends on managing safety concerns and securing funding, and a simpler P/S ratio cross-check raises valuation risks.
Beam Therapeutics completes dosing in sickle cell trial
Beam Therapeutics announced the completion of dosing for adult and adolescent patients in its Phase 1/2 BEACON trial for sickle cell disease, with a biologics license application expected by late 2026 and updated data by year-end. The company also reported progress in other trials, including BEAM-302 for alpha-1 antitrypsin deficiency and BEAM-304 for phenylketonuria, and detailed its financial position with $1.2 billion in cash and equivalents.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates
Beam Therapeutics Inc. (BEAM) reported a Q2 loss of $1.18 per share, missing the Zacks Consensus Estimate of a $1 loss and underperforming the previous year's loss of $1 per share. The company's revenues for the quarter were $0.49 million, significantly below the Zacks Consensus Estimate of $30.33 million and down from $8.47 million a year ago. Despite underperforming the S&P 500 year-to-date, the stock currently holds a Zacks Rank #3 (Hold), indicating an expected in-line performance with the market.
Beam Therapeutics Inc. 2Q 2026: Revenue $0.5M, EPS $(1.18) — 10-Q Summary
Beam Therapeutics Inc. reported its second-quarter 2026 results, showing a revenue of $0.5 million and a diluted loss per share of $(1.18). The company also highlighted clinical progress with its BEACON risto-cel program targeting a BLA filing by year-end 2026, advancing LNP programs, and ongoing strategic collaborations. A new 100k sq ft cGMP facility is now online to support both ex vivo and in vivo programs.
Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q2 Revenue $490,000, vs. FactSet Est of $16.4M
Beam Therapeutics Inc. reported Q2 revenue of $490,000, significantly missing the FactSet estimate of $16.4 million. The company also posted a Q2 loss of $1.18 per share, which was higher than the FactSet estimated loss of $1.11 per share. This financial update indicates a challenging quarter for the biotechnology firm.
Beam Therapeutics (NASDAQ: BEAM) details Q2 loss, $1.2B cash and pipeline plans
Beam Therapeutics reported a Q2 2026 net loss of $122.7 million ($1.18 per share) on $490 thousand in license and collaboration revenue, ending the quarter with $1.2 billion in cash. The company expects this capital, plus an additional $200 million from a credit facility, to fund operations into mid-2029. Beam highlighted significant clinical progress, including dosing the first patient in the pivotal BEAM-302 AATD trial, completing dosing in the BEACON risto-cel SCD trial with a BLA submission anticipated by year-end 2026, and FDA clearance of the IND for BEAM-304 in PKU.
Beam Therapeutics Inc (BEAM) Institutional Confidence
Beam Therapeutics Inc (BEAM) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional shareholding stands at 103.20%, a decrease of 9.85% quarter-over-quarter. Catherine Wood is the largest institutional shareholder, holding 9.07 million shares, which represents 12.21% of outstanding shares.
Beam Therapeutics Inc (BEAM) Financial Health: Profitability & Balance Sheet Analysis
Beam Therapeutics Inc.'s (BEAM) financial score is 7.49, indicating a stable financial status but low operating efficiency within the Biotechnology & Medical Research industry. The company reported a 324.87% year-over-year revenue increase to $31.74M and a 13.68% increase in net profit. The analysis provides scores across various financial dimensions like Quality of Earnings and Growth Potential, noting that relevant data for some metrics have not yet been disclosed by the company.
Beam Therapeutics (BEAM) CMO sells 16,667 shares under 10b5-1 plan
Beam Therapeutics' Chief Medical Officer, Simon Amy, sold 16,667 shares of common stock on July 27, 2026, at a weighted average price of $25.7417 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2026. Following the transactions, Amy directly holds 85,696 shares of Beam Therapeutics common stock.
Beam Therapeutics Inc (BEAM) Cash Flow
This article provides a detailed cash flow statement for Beam Therapeutics Inc (BEAM), including operating, investing, and financing cash flows presented quarterly and annually. It also includes key financial figures such as net income, capital expenditures, and free cash flow, alongside answers to frequently asked questions about these financial metrics. The data covers various fiscal quarters from FY2018Q3 through FY2026Q1, offering a comprehensive view of the company's financial performance.
Responsive Playbooks and the BEAM Inflection
This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM), noting weak near and mid-term sentiment despite a long-term positive outlook. It identifies key signals, support, and resistance levels, and provides three AI-generated trading strategies tailored for different risk profiles, emphasizing risk management.
BEAM|Beam Therapeutics Inc|Price:26.300|Chg%:+1.230
This article provides a comprehensive stock analysis of Beam Therapeutics Inc (BEAM) by TradingKey, detailing its financial health, valuation, growth potential, and institutional confidence. The company-s fundamentals are considered healthy with high growth potential, and its valuation is deemed fairly valued within the Biotechnology & Medical Research industry. Analysts have a "Buy" rating for BEAM, with a high price target of $51.02.
Beam Therapeutics (BEAM) Revenue Breakdown - Main Composition
This article provides a detailed breakdown of Beam Therapeutics' revenue composition, showing the contribution of each segment to the company's total revenue. Such insights are crucial for investors and analysts to understand the core drivers of Beam Therapeutics' financial performance and future growth prospects.
Beam Therapeutics Inc (BEAM) Earnings Forecast: Future EPS & Revenue Growth Estimates
Beam Therapeutics Inc (BEAM) has an earnings forecast score of 8.74, ranking 68th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $42.00, with a strong buy recommendation based on 17 analysts. The company's expected revenue for the next quarter is $16.37 million, and EPS for the previous quarter was $2.37 against an expectation of $-0.91.
Beam Therapeutics Inc (BEAM) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides an overview of Beam Therapeutics Inc (BEAM) focusing on its dividend and stock split history. It states that BEAM has not distributed any dividends in the past five years. The page also includes real-time stock data and company profile links.
BEAM|Beam Therapeutics Inc|Price:25.100|Chg%:-0.810
This article provides a detailed company profile for Beam Therapeutics Inc. (BEAM), a biotechnology company focused on developing precision genetic medicines using base editing technology. It covers the company's background, business scope, key treatments like BEAM-101 and BEAM-302, financial data, market performance, executive team, and major shareholders.
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
Beam Therapeutics announced it will present updated clinical data from its Phase 1/2 trial of BEAM-302 for alpha-1 antitrypsin deficiency (AATD) at the European Respiratory Society Congress 2026. This genetic medicine aims to address both liver and lung complications of AATD by correcting the PiZ mutation. The company will also host an investor webcast to discuss these updates.
Beam Therapeutics to present BEAM-302 data at September conference
Beam Therapeutics announced it will present updated clinical data for BEAM-302, its therapy for alpha-1 antitrypsin deficiency, at the European Respiratory Society Congress in September 2026. The therapy uses base editing to correct the PiZ mutation and has shown durable correction and physiological AAT level increases in patients. The company will host an investor webcast to discuss the data.
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
Beam Therapeutics will present updated clinical data from its Phase 1/2 trial of BEAM-302 for alpha-1 antitrypsin deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026. This late-breaking oral presentation will highlight BEAM-302, a genetic medicine designed to address both lung and liver disease in AATD patients by correcting the PiZ mutation. The company will also host an investor webcast to discuss the clinical data.
Beam Therapeutics to Present BEAM-302 Data at ERS 2026 | BEAM Stock News
Beam Therapeutics (Nasdaq: BEAM) will present updated clinical data from its Phase 1/2 trial of BEAM-302 for alpha-1 antitrypsin deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 on September 8, 2026. BEAM-302 is a liver-targeting base-editing therapy designed to address both lung and liver manifestations of AATD by restoring AAT levels and function while eliminating toxic Z-AAT. The company also plans an investor conference call and webcast on the same day to discuss these updates.
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
Beam Therapeutics announced it will present updated clinical data from its Phase 1/2 trial for BEAM-302, a treatment for alpha-1 antitrypsin deficiency (AATD), at the European Respiratory Society (ERS) Congress 2026. BEAM-302 is a genetic medicine designed to correct the underlying pathophysiology of both liver and lung disease in AATD patients. The company plans to host an investor webcast on September 8, 2026, to discuss these clinical updates.
Beam Therapeutics to Present Updated Data from Phase 1/2
Beam Therapeutics announced it will present updated clinical data from its Phase 1/2 trial of BEAM-302 for alpha-1 antitrypsin deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026. The company will also host an investor webcast to discuss the data. BEAM-302 is a liver-targeting therapy designed to correct the PiZ mutation, addressing both liver and lung disease by reducing toxic Z-AAT and increasing functional AAT.
Beam Therapeutics (BEAM) Following Ark Invest Interest And Clinical Milestones Looks Undervalued
Beam Therapeutics (BEAM) is considered undervalued by Simply Wall St after an Ark Invest position increase and upcoming clinical milestones. Despite recent share price weakness, the company's gene editing pipeline, particularly the ESCAPE technology and nominated BEAM-103 and BEAM-104 programs, are seen as significant revenue drivers. However, the associated risks include managing busulfan safety concerns, securing funding, and the high Price-to-Sales ratio compared to the industry.
Beam Therapeutics (BEAM) Following Ark Invest Interest And Clinical Milestones Looks Undervalued
Beam Therapeutics (BEAM) is attracting attention due to Ark Invest's increased position and upcoming clinical milestones, including a global BEAM-302 trial. Despite a recent share price pullback, analysts view the stock as significantly undervalued, with a narrative fair value of $51.07 based on its gene editing pipeline and ESCAPE technology. However, the company still faces clinical and earnings risks, and its high Price/Sales ratio compared to the industry average suggests potential valuation concerns for investors.
Beam Therapeutics Stock 9-Day Losing Spree: Stock Falls 31%
Beam Therapeutics (NASDAQ: BEAM) has experienced a nine-day losing streak, with its stock falling 31% during this period. The article highlights this significant decline in the company's stock performance.
9 Red Days In A Row: Beam Therapeutics Stock Is Down 31%
Beam Therapeutics (BEAM) stock has dropped 31% over nine consecutive trading days, erasing $1.2 billion from its market value. This decline is attributed to the company's significant operating losses, despite strong revenue growth. The article suggests that while losing streaks draw attention, investors should re-examine the company's fundamentals rather than reacting solely to the stock's momentum.
8 Red Days In A Row: Beam Therapeutics Stock Is Down 27%
Beam Therapeutics (BEAM) stock has experienced a significant downturn, falling 27.4% over 8 consecutive trading days, resulting in a $1.1 billion market value loss. This decline highlights a conflict between the company's strong revenue growth (158.0%) and its negative operating margin (-226.6%). The article suggests that such streaks are a signal for investors to re-evaluate fundamentals rather than react impulsively.
8 Red Days In A Row: Beam Therapeutics Stock Is Down 27%
Beam Therapeutics (BEAM) stock has experienced an 8-day losing streak, resulting in a 27.4% cumulative loss and a $1.1 billion reduction in market value. This significant slide is attributed to a conflict between the company's high revenue growth (158%) and its considerable negative operating margin (-226.6%). While the S&P 500 remained relatively stable during this period, the article suggests using such market signals to re-evaluate fundamentals rather than acting solely on momentum, advising investors to look at diversified portfolios or use "Buy the Dip" strategies for marked-down stocks.
ETFs Investing in Beam Therapeutics, Inc. Stocks
This article lists various ETFs that hold stocks of Beam Therapeutics, Inc. The ETFs are sorted by market value and provide details such as weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, and NAV total return over three years. This information helps investors identify diversified investment opportunities related to Beam Therapeutics with potentially lower risk.
Understanding the Setup: (BEAM) and Scalable Risk
This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM), noting weak near and mid-term sentiment despite a positive long-term outlook. It highlights that a breakdown is underway with expected lower levels and elevated downside risk. The analysis provides institutional trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Beam Therapeutics Stock 6-Day Losing Spree: Stock Falls 19%
Beam Therapeutics (NASDAQ: BEAM) stock has experienced a significant downturn, falling 19% over a six-day losing streak. This article reports on the stock's recent performance.
